BTEC:SW:SW-iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) USD (USD)

ETF | Others |

Last Closing

USD 6.373

Change

-0.04 (-0.58)%

Market Cap

N/A

Volume

1.21K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-08 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
CHDIV:SW UBS ETF (CH) - MSCI Switzerlan..

+0.03 (+0.23%)

USD 1,244,681.59B
SWICHA:SW UBS ETF (CH) – MSCI Switzerl..

+0.07 (+0.34%)

USD 226,274.25B
SWUSAH:SW UBS ETF (CH) – MSCI Switzerl..

+0.29 (+1.07%)

USD 226,274.21B
SWEUAH:SW UBS ETF (CH) – MSCI Switzerl..

N/A

USD 226,274.20B
RGLDS:SW Raiffeisen ETF Solid Gold A US..

+65.00 (+0.81%)

USD 134,034.93B
RGLDSH:SW Raiffeisen ETF Solid Gold H CH..

+43.00 (+0.82%)

USD 134,034.91B
RGLDOH:SW Raiffeisen ETF Solid Gold Ounc..

+17.60 (+1.07%)

USD 134,034.86B
RGLDO:SW Raiffeisen ETF Solid Gold Ounc..

+13.00 (+0.57%)

USD 134,034.85B
SPICHA:SW UBS ETF (CH) – SPI® (CHF) A..

+0.21 (+0.28%)

USD 131,872.43B
SPMCHA:SW UBS ETF (CH) – SPI® Mid (CH..

-0.08 (-0.07%)

USD 130,595.12B

ETFs Containing BTEC:SW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.20% 85% B 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.20% 85% B 80% B-
Trailing 12 Months  
Capital Gain -0.39% 12% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.39% 10% F 14% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 5.71% 56% F 57% F
Dividend Return 5.71% 56% F 57% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.25% 52% F 58% F
Risk Adjusted Return 69.28% 51% F 56% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike